Cidara Therapeutics Inc (CDTX)
14.08
+0.14
(+1.00%)
USD |
NASDAQ |
Nov 14, 12:46
Cidara Therapeutics Cash from Investing (Quarterly): 0.00 for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| March 31, 2024 | -0.023M |
| December 31, 2023 | -0.178M |
| September 30, 2023 | -0.126M |
| June 30, 2023 | -0.107M |
| March 31, 2023 | -0.094M |
| December 31, 2022 | -0.009M |
| September 30, 2022 | -0.009M |
| June 30, 2022 | -0.016M |
| March 31, 2022 | -0.084M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | -0.012M |
| June 30, 2021 | -0.017M |
| March 31, 2021 | -0.012M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | -0.054M |
| June 30, 2020 | -0.096M |
| March 31, 2020 | -0.036M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | -0.026M |
| Date | Value |
|---|---|
| March 31, 2019 | -0.009M |
| December 31, 2018 | 4.46M |
| September 30, 2018 | 9.688M |
| June 30, 2018 | -0.298M |
| March 31, 2018 | 0.451M |
| December 31, 2017 | -4.783M |
| September 30, 2017 | -9.871M |
| June 30, 2017 | 7.841M |
| March 31, 2017 | 11.28M |
| December 31, 2016 | 35.39M |
| September 30, 2016 | 3.095M |
| June 30, 2016 | -12.99M |
| March 31, 2016 | -0.013M |
| December 31, 2015 | 4.558M |
| September 30, 2015 | -50.49M |
| June 30, 2015 | -0.126M |
| March 31, 2015 | -0.031M |
| December 31, 2014 | -0.146M |
| September 30, 2014 | -0.167M |
| June 30, 2014 | -0.677M |
| March 31, 2014 | -0.001M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-0.178M
Minimum
Dec 2023
--
Maximum
Dec 2019
-0.0459M
Average
-0.017M
Median
Jun 2021
Cash from Investing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -16.16M |
| Arbutus Biopharma Corp | -11.99M |
| GlycoMimetics Inc | -0.0025M |
| FibroGen Inc | 72.24M |
| Cue Biopharma Inc | -0.01M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -103.78M |
| Cash from Financing (Quarterly) | 239.13M |
| Free Cash Flow | -125.11M |
| Free Cash Flow Per Share (Quarterly) | -22.74 |
| Free Cash Flow to Equity (Quarterly) | -103.78M |
| Free Cash Flow to Firm (Quarterly) | -103.78M |
| Free Cash Flow Yield | -195.9% |